PEN Stock Analysis: Penumbra | NYSE
Medical Devices | NYSE, USA | Market Cap: 12.670m USD | 12M Return: 15.1% | US70975L1070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 120M
EPS Trend: 97.8%
Qual. Beats: -3
Rev. Trend: 99.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.1 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Penumbra, Inc. (NYSE: PEN) is a U.S.-based medical device company that designs, develops, manufactures, and markets products for vascular and neurovascular conditions. Founded in 2004 and headquartered in Alameda, California, the company went public in September 2015 and currently carries a large-cap market capitalization. Its products are sold both domestically and internationally through a combination of direct sales organizations and third-party distributors.
The companys portfolio is anchored by mechanical and computer-assisted vacuum thrombectomy systems - including the Indigo System, Lightning Flash, and Lightning Bolt 7 platforms - used to remove blood clots from peripheral and arterial vasculature. Beyond thrombectomy, Penumbra offers a broad line of access catheters (under the Neuron, BENCHMARK, and BMX brands, among others), neuro embolization coils for treating aneurysms, peripheral embolization products such as the Ruby Embolization Platform, and neurosurgical tools like the Artemis Neuro Evacuation Device. The mechanical thrombectomy category sits within the broader minimally invasive vascular intervention market, where catheter-based clot removal has become a standard-of-care intervention for conditions such as acute ischemic stroke.
Operating in the regulated medical device industry, Penumbra is subject to significant clinical and regulatory requirements, including FDA approval pathways in the United States. Its diversified portfolio spans peripheral vascular, neurovascular, and neurosurgical applications, allowing the company to address multiple end markets within the interventional medicine space.
- Lightning Flash thrombectomy adoption accelerates vascular revenue growth
- Competition from Stryker and Inari pressures market share
- Operating margins pressured by elevated R&D and sales investment
| Net Income: 157.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.14 > 1.0 |
| NWC/Revenue: 73.24% < 20% (prev 72.87%; Δ 0.37% < -1%) |
| CFO/TA 0.13 > 3% & CFO 261.0m > Net Income 157.0m |
| Net Debt (-464.2m) to EBITDA (229.2m): -2.03 < 3 |
| Current Ratio: 5.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.6m) vs 12m ago 0.81% < -2% |
| Gross Margin: 67.98% > 18% (prev 66.80%; Δ 1.18% > 0.5%) |
| Asset Turnover: 82.79% > 50% (prev 76.46%; Δ 6.32% > 0%) |
| Interest Coverage Ratio: 165.2 > 6 (EBIT TTM 209.1m / Interest Expense TTM 1.27m) |
| A: 0.56 (Total Current Assets 1.38b - Total Current Liabilities 233.8m) / Total Assets 2.03b |
| B: 0.17 (Retained Earnings 347.4m / Total Assets 2.03b) |
| C: 0.11 (EBIT TTM 209.1m / Avg Total Assets 1.88b) |
| D: 3.59 (Book Value of Equity 1.58b / Total Liabilities 441.6m) |
| Altman-Z'' = 8.77 = AAA |
| DSRI: 0.91 (Receivables 195.2m/183.4m, Revenue 1.56b/1.33b) |
| GMI: 0.98 (GM 66.80% / 67.98%) |
| AQI: 0.85 (AQ_t 0.15 / AQ_t-1 0.18) |
| SGI: 1.17 (Revenue 1.56b / 1.33b) |
| TATA: -0.05 (NI 157.0m - CFO 261.0m) / TA 2.03b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of November 17, 2026, the stock is trading at USD 320.62 with a total of 250,366 shares traded. Over the past week, the price has changed by -0.38%, over one month by -0.07%, over three months by -2.00% and over the past year by +15.12%.
Current recommended Stop Loss: 317.60 (which is 0.9% or 1.2 ATR below the current price).
Penumbra has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold PEN.
- StrongBuy: 2
- Buy: 1
- Hold: 14
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 362.5 | 13.1% |
P/E Trailing = 80.9723
P/E Forward = 56.1798
P/S = 8.1202
P/B = 8.011
P/EG = 3.6269
Revenue TTM = 1.56b USD
EBIT TTM = 209.1m USD
EBITDA TTM = 229.2m USD
Long Term Debt = 20.7m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 17.1m USD (from shortTermDebt, last quarter)
Debt = 209.4m USD (from shortLongTermDebtTotal, last quarter) (leases 209.4m already included)
Net Debt = -464.2m USD (calculated: Debt 209.4m - CCE 673.6m)
Enterprise Value = 12.2b USD (12.7b + Debt 209.4m - CCE 673.6m)
Interest Coverage Ratio = 165.2 (Ebit TTM 209.1m / Interest Expense TTM 1.27m)
EV/FCF = 60.94x (Enterprise Value 12.2b / FCF TTM 200.3m)
FCF Yield = 1.64% (FCF TTM 200.3m / Enterprise Value 12.2b)
FCF Margin = 12.84% (FCF TTM 200.3m / Revenue TTM 1.56b)
Net Margin = 10.06% (Net Income TTM 157.0m / Revenue TTM 1.56b)
Gross Margin = 67.98% ((Revenue TTM 1.56b - Cost of Revenue TTM 499.5m) / Revenue TTM)
Gross Margin QoQ = 68.34% (prev 67.93%)
Tobins Q-Ratio = 6.03 (Enterprise Value 12.2b / Total Assets 2.03b)
Interest Expense / Debt = 0.60% (Interest Expense 1.27m / Debt 209.4m)
Taxrate = 24.45% (50.8m / 207.8m)
NOPAT = 158.0m (EBIT 209.1m * (1 - 24.45%))
Current Ratio = 5.89 (Total Current Assets 1.38b / Total Current Liabilities 233.8m)
Debt / Equity = 0.13 (Debt 209.4m / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = -2.03 (Net Debt -464.2m / EBITDA 229.2m)
Debt / FCF = -2.32 (Net Debt -464.2m / FCF TTM 200.3m)
Total Stockholder Equity = 1.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.33% (Net Income 157.0m / Total Assets 2.03b)
RoE = 10.44% (Net Income TTM 157.0m / Total Stockholder Equity 1.50b)
RoCE = 13.71% (EBIT 209.1m / Capital Employed (Equity 1.50b + L.T.Debt 20.7m))
RoIC = 9.13% (NOPAT 158.0m / Invested Capital 1.73b)
WACC = 7.01% (E(12.7b)/V(12.9b) * Re(7.12%) + D(209.4m)/V(12.9b) * Rd(0.60%) * (1-Tc(0.24)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.48 | Cagr: 0.94%
[DCF] Terminal Value 77.97% ; FCFF base≈181.2m ; Y1≈207.7m ; Y5≈305.7m
[DCF] Fair Price = 128.5 (EV 4.60b - Net Debt -464.2m = Equity 5.07b / Shares 39.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.77 | EPS CAGR: 29.88% | SUE: -1.00 | # QB: -3
Revenue Correlation: 99.76 | Revenue CAGR: 15.28% | SUE: 1.53 | # QB: 1
EPS current Quarter (2027-03-31): EPS=1.40 | Chg30d=+0.85% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=4.90 | Chg30d=+2.43% | Revisions=-50% | GrowthEPS=+27.7% | GrowthRev=+14.4%
EPS next Year (2027-12-31): EPS=6.16 | Chg30d=+0.48% | Revisions=-17% | GrowthEPS=+25.7% | GrowthRev=+12.6%
[Analyst] Revisions Ratio: -50% (up=1, down=6)